THE INSTITUTE FOR CANCER RESEARCH

The Institute for Cancer Research specializes in preclinical biotechnology research focused on cancer prevention, with deep expertise in identifying and validating intermediate endpoint biomarkers to accelerate drug development. Their work centers on mechanistic targeting of oncogenic pathways—including STAT3, IL-6/GP130, and microbial metabolite mimicry—to develop novel immunopreventive and chemopreventive agents for high-risk populations such as those with Lynch syndrome, FAP, or colitis-associated cancer. They design and evaluate next-generation small molecule inhibitors, microbial-targeted vaccines, and nano-drug platforms, integrating molecular pharmacology, translational biomarker discovery, and preclinical efficacy modeling to bridge laboratory findings with clinical translation. Their technical differentiators lie in precision targeting of tumor microenvironment signals and leveraging host-microbiome interactions for cancer interception. The organization maintains a sustained, mission-aligned partnership with the Department of Health and Human Services, delivering research under the PREVENT Preclinical Drug Development Program. Their engagements consistently support HHS’s cancer interception initiative, focusing on mechanistic validation of preventive therapeutics and biomarker-driven endpoints to de-risk candidates prior to clinical trials. Their primary industry focus is in Research and Development in Biotechnology (NAICS 541714), where they operate at the intersection of molecular oncology, immunology, and microbiome science. They are positioned as a specialized R&D provider for preventive oncology, distinguishing themselves through targeted approaches to hereditary and inflammation-driven cancers rather than broad therapeutic development. As an 8H entity based in Philadelphia, PA, The Institute for Cancer Research operates as a non-federal research organization with no federal certifications on record. Their geographic and institutional footprint anchors them within the U.S. biomedical research ecosystem, serving as a trusted non-profit partner for federal cancer prevention initiatives.